RxCelerate
David Mosedale is a seasoned professional in the life sciences sector with extensive experience in various leadership roles. Currently serving as VP of ProQuant at RXCELERATE LIMITED since April 2023, Mosedale was previously the Chief Technology Officer at Methuselah Health UK Ltd., where work involved studying proteome instability in age-related diseases. Prior to that, Mosedale held the position of Chief Scientific Officer at Total Scientific Ltd., overseeing contract research services. Additional roles include VP of Research and Development at Pronostics Ltd., where responsibilities encompassed multiplex diagnostic tests development, and Principal Investigator at Papworth Hospital NHS Foundation Trust, leading significant clinical studies. Mosedale began professional training as a post-doctoral researcher at the University of Cambridge after earning an MA in Biochemistry from the same institution.
This person is not in any teams
RxCelerate
1 followers
RxCelerate Limited is a leading outsourced drug development company based in Cambridge (U.K) delivering complete preclinical programmes to our clients. We offer a comprehensive suite of services under one roof, including in silico modelling, medicinal chemistry, in vitro and preclinical capabilities, and project management. We pride ourselves on our ability to deliver innovative cutting-edge experimental solutions that save our clients time and money. Our flexible approach, commitment to quality, and ability to deliver results quickly make us the perfect partner for unlocking the true potential of your drug development journey. We are not just a company; we are a people-first organisation. We invest in and value our employees and have created an environment that encourages collaboration, innovation and personal growth. We foster a culture of inclusivity, where every team member’s voice is heard, and their ideas are valued. Connect with us to be part of our exciting journey!